Previous 10 |
~ 88% reduction in median Annualized Bleeding Rate (ABR) for all bleeds and 94% reduction in median ABR for spontaneous joint bleeds in highest dose tested ~ ~ SerpinPC observed to be well-tolerated ~ ~ Company has initiated planning for global registrational program ~ ...
CAMBRIDGE, Mass. & LONDON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, M.D., Ph.D., Chief Executive Officer, will participate in an analyst-led fireside chat at the Morgan Stanley Virtual 19th Annual Global Healthcare...
~ Successful completion of an initial public offering of American Depositary Shares raising gross proceeds of $379.5 million to help advance portfolio of 16 clinical and preclinical programs ~ ~ Centessa leadership team strengthened through appointment of key industry executives...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Big Tech will be in the spotlight next with the U.S. House Judiciary Committee expected to vote on a package on antitrus...
CAMBRIDGE, Mass. and LONDON, June 07, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, M.D., Ph.D., Chief Executive Officer, will participate in an analyst-led fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Confer...
Citi, acting through Citibank N.A., has been appointed by Centessa Pharmaceuticals plc (“Centessa”), a next-generation biopharmaceutical company, to act as depositary bank for its American Depositary Receipt (“ADR”) programme. Centessa’s American D...
CAMBRIDGE, Mass. and LONDON, June 04, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Centessa”), a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, announced ...
News, Short Squeeze, Breakout and More Instantly...
Centessa Pharmaceuticals plc Company Name:
CNTA Stock Symbol:
NASDAQ Market:
Centessa Pharmaceuticals plc Website:
2024-06-21 11:15:04 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for CNTA on June 21, 2024 09:17AM ET. The previous analyst recommendation was Equal-Weight. CNTA was trading at $9.28 at issue of the analyst recommendation. The overall analyst consensus : ...
BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Fi...
Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 interim analysis planned in 2024 Orexin Agonist Program: Cleared IND and initiated Phase 1 first-in-human clinical trial of ORX750, a highly potent and sel...